Gateways Hospital and Mental Health Center Opens New Sensory Room, Providing Vulnerable Clients with Innovative, Client-Centered Care

Our Bureau

Gateways Hospital and Mental Health Center unveiled its groundbreaking Sensory Room, a pioneering addition to acute patient care in Los Angeles, generously funded by a $45,000 grant from the Robert Ellis Simon Foundation. This innovative space signifies Gateways’ commitment to implementing client-centered approaches, blending the latest inpatient psychiatric care practices with immersive sensory […]

New Paper Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, Demonstrates Correlation Between the Presence of Misfolded α-Synuclein and Clinical Presentations of Alzheimer’s Disease

Our Bureau

Amprion is pleased to be affiliated with a new scientific paper published in Alzheimer’s & Dementia, entitled “Investigating alpha-synuclein co-pathology in Alzheimer’s disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay,” led by University of Perugia Professor, Dr. Lucilla Parnetti and Amprion Director of Research and Development, Dr. Luis Concha-Marambio. In this study, […]

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Reports Comments by Strategic Partner Lotus Pharmaceutical Co. Ltd. (1975.TW) in Recent Financial Report

Our Bureau

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that its Asia Pacific strategic partner Lotus Pharmaceutical Co. Ltd (1975.TW) identified enrollment completion of the NRx clinical trial in bipolar depression as a material event in is February 7 financial filing.[1]  Lotus provides the Asia Pacific component of NRx’s global partnership […]

Human Change campaign launched at World Economic Forum in Davos to make children’s mental health a global priority

Our Bureau

The global advocacy campaign, Human Change, was launched today in Davos at the World Economic Forum to raise awareness and drive transformation in the way children approach social media and the digitization of their lives. The campaign, founded by Margarita Louis-Dreyfus, brings together people from all walks of life – academics, pediatricians, advocates, […]

Darmiyan Receives FDA Approval for BrainSee, the First Prognostic Test for Predicting Likelihood of Progression to Alzheimer’s Dementia

Our Bureau

Today marks a turning point in the battle against Alzheimer’s disease as Darmiyan, Inc., a leading company in brain health innovation announces the FDA’s approval of its first-in-class (De Novo) clinical test, BrainSee. This approval marks a pivotal advancement in brain health and opens the door to untapped market potential in […]

The Human Change campaign launched at World Economic Forum in Davos to make children’s mental health a global priority

Our Bureau

Global advocacy campaign, Human Change, launched today in Davos during the World Economic Forum to raise awareness and instigate a transformation in the way children approach social media and the digitalisation of their lives. The campaign, founded by Margarita Louis-Dreyfus, is uniting people from all walks of life –academics, paediatricians, advocates, practitioners, teachers and […]

Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)

Our Bureau

Alkermes plc (Nasdaq: ALKS) today announced topline results from a phase 3, open-label extension study assessing the long-term safety, tolerability and durability of treatment effect of LYBALVI® (olanzapine and samidorphan) in patients with schizophrenia, schizophreniform disorder or bipolar I disorder for up to four years of treatment, following treatment received in prior LYBALVI […]

NRx Pharmaceuticals (Nasdaq: NRXP) to Present Keynote Address on Ketamine Efficacy and Risks at Upcoming Sachs Neuroscience Innovation Forum in San Francisco

Our Bureau

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, (NRx), a clinical-stage biopharmaceutical company today announced that it has been selected to give the keynote address entitled “Ketamine for Suicidal Depression: The Benefits are Clear, But So are the Risks,” at the upcoming Sachs Neuroscience Innovation Forum in San Francisco, CA on January 7, 2024. The […]

Subscribe Now